Product
Netarsudil 0.02% Ophthalmic Solution
1 clinical trial
2 indications
Indication
Retinal DetachmentIndication
Proliferative VitreoretinopathyClinical trial
A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Study on the Use of Rho-Kinase Inhibitor to Reduce Ore Prevent Proliferative Vitreoretinopathy (PVR) in Eyes With Rhegmatogenous Retinal Detachment (RRD) at High Risk of PVRStatus: Recruiting, Estimated PCD: 2023-12-31